Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
暂无分享，去创建一个
V. Seshan | A. Zelenetz | O. Abdel-Wahab | A. Dogan | A. Mato | J. Abramson | A. Ni | E. Hochberg | M. Palomba | A. Jacob | M. Matasar | Anita Kumar | A. Noy | Puja Chadha | T. Takvorian | M. Roshal | E. Joffe | J. Barnes | L. Roeker | J. Soumerai | S. Hughes | C. Owens | C. Batlevi | A. Hamilton | B. McGree | Jane E. Huang | Daneal Portman | J. Lynch | Meghan C Thompson | P. Johnson | J. Biondo | M. Choma | Colette N Owens | Q. Wu | K. Flaherty | J. Carter | Chaya Friedman | Elizabeth Simkins | Jade Ruiters | Sidney Sechio | L. Ramos | Natascha Nolet | Neena Mahajan | R. Martignetti | Joanna Mi | K. Scorsune | Clare Grieve | Meghan C. Thompson | C. Friedman | A. Dogan